Charles River teams with Lilly TuneLab to provide nonclinical testing for AI-driven drug discovery platform

Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

CRL

0.00
  • Charles River Laboratories entered a collaboration with Lilly TuneLab, Eli Lilly’s AI/ML drug discovery platform.
  • Agreement positions Charles River to provide nonclinical testing services to companies participating in TuneLab.
  • Partnership aims to speed candidate selection by pairing TuneLab’s federated-learning models with standardized nonclinical testing protocols.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260618961171) on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.